Fezakinumab
Fezakinumab
Fezakinumab (pronounced fez-a-ki-num-ab) is a monoclonal antibody designed for the treatment of various autoimmune diseases. It is a type of biologic therapy that targets and neutralizes interleukin-22 (IL-22), a protein that plays a key role in the pathogenesis of several autoimmune conditions.
Etymology
The name "Fezakinumab" is derived from the International Nonproprietary Names (INN), where "Feza" is a prefix used for monoclonal antibodies, "kinu" refers to the interleukin-22 (IL-22) target, and "mab" is a suffix for monoclonal antibodies.
Usage
Fezakinumab is currently being studied for its potential use in treating a variety of autoimmune diseases, including psoriasis, rheumatoid arthritis, and Crohn's disease. By targeting and neutralizing IL-22, Fezakinumab may help to reduce inflammation and slow disease progression.
Related Terms
- Monoclonal Antibodies: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Interleukin-22 (IL-22): A cytokine that plays an important role in the body's immune response.
- Autoimmune Diseases: Conditions in which your immune system mistakenly attacks your body.
- Biologic Therapy: Treatment that uses substances made from living organisms to treat disease.
See Also
External links
- Medical encyclopedia article on Fezakinumab
- Wikipedia's article - Fezakinumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski